Effects of Two Administration Schemes of Intramuscular Clodronic Acid on Bone Mineral Density
- Prof Bruno Frediani
- … show all 1 hide
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background: Clodronic acid is a bisphosphonate used in the prevention and treatment of postmenopausal bone loss. Previous evidence suggests a direct dose-response relationship for the densitometric effect of clodronic acid. Therefore, as it is widely accepted that a reduction in the dosing frequency of bisphosphonates may improve adherence and therefore therapeutic outcomes, an increase in the interval between consecutive administrations of clodronic acid might be associated with a concomitant increase in the overall bisphosphonate dose received. However, to our knowledge, a direct comparison of the effects of intramuscular clodronic acid 100 mg once weekly with a regimen consisting of a higher dose and a longer interval between two consecutive administrations is still lacking.
Objective: This study compared the increase in bone mineral density (BMD) achieved with two different administration schemes of intramuscular clodronic acid (100 mg once weekly and 200 mg every 2 weeks) in patients with postmenopausal osteoporosis.
Study Design and Setting: This randomized, open-label, parallel-group trial was conducted in the Osteoporosis and Instrumental Diagnosis Center ‘OsteoArticolar’ (University of Siena, Siena, Italy) between January 2007 and December 2009.
Patients: Consecutive women aged 50–80 years with postmenopausal osteoporosis, diagnosed ≥5 years prior to inclusion in the study, were eligible for participation in this study.
Intervention: Patients were randomized to receive either intramuscular clodronic acid (Clasteon®) 100 mg (group A) + lidocaine (lignocaine) once weekly or intramuscular clodronic acid 100mg+lidocaine for two consecutive days every 2 weeks (group B), for 2 years.
Results: In total, 30 patients were randomized to group A and 30 patients to group B. Significant increases in mean ±SD BMD of the lumbar spine versus baseline values were observed in both groups at 1 and 2 year(s) from treatment initiation (group A —year 1: +2.8%±1.7%, p<0.05; year 2: +3.5% ±f-2.2%, p < 0.01; group B —year 1: +2.7% ±2.1 %, p < 0.05; year 2: +3.9% ±2.2%, p<0.01). Mean ±SD BMD at the femoral neck also significantly increased versus baseline in group A at both timepoints (year 1: +2.3% ±1.9%, p < 0.05; year 2: +2.5% ±1.9%, p < 0.05), while the increase reported in group B was significant only after 2 years of treatment (year 1: +1.9% ±2.2%; year 2: +2.8% ±1.8%; p<0.05). Significant mean ±SD increases in total femur BMD were observed only in group A at 2 years (+2.4%±1.9, p<0.05). No differences between study groups were reported. Two non-traumatic vertebral fractures were observed in group A (6.6%) and three in group B (10.0%). Treatment was well tolerated; mild pain at injection site was observed in three patients (one in group A, 3.3%; two in group B, 6.6%).
Conclusion: This randomized study suggests, for the first time to the author’s knowledge, a similar effect of intramuscular clodronic acid 100mg once weekly and 200mg every 2 weeks (two 100mg administrations on two consecutive days) on BMD in women with postmenopausal osteoporosis. The administration of intramuscular clodronic acid 200 mg every 2 weeks may therefore represent a new therapeutic option in the treatment of postmenopausal osteoporosis.
- Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961–78 CrossRef
- Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12 (20 Pt 2): 6222–30s CrossRef
- Adami S, Guarrera G, Salvagno G, et al. Sequential treatment of Paget’s disease with human calcitonin and dichloromethylene diphosphonate (C12MDP). Metab Bone Dis Relat Res 1984; 5: 265–7 CrossRef
- Adami S, Bolzicco GP, Rizzo A, et al. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcaemia of malignancy. Bone Miner 1987; 2: 395–404
- Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996; 22: 265–87 CrossRef
- Kanis JA, Powles T, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19: 663–7 CrossRef
- Kanis JA, McCloskey EV, Sirtori P, et al. Rationale for the use of clodronate in osteoporosis. Osteopor Int 1993; 2Suppl.: 23–8 CrossRef
- Koivukangas A, Tuukkanen J, Hannuniemi R, et al. Effects of long-term administration of clodronate on growing rat bone. Calcif Tissue Int 2001; 69: 350–5 CrossRef
- Tauchmanova L, Guerra E, Pivonello R, et al. Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing’s syndrome. J Endocrinol Invest 2009; 32: 390–4
- Lahtinen R, Laakso M, Palva I, et al., for the Finnish Leukaemia Group. Randomised placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet} 1992}; 340}: 1049–52 CrossRef
- Paterson A, Powles T, Kanis J, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65
- McCloskey EV, Dunn JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomised trial of clodronate in multiple myeloma. Br J Haematol 2001; 113: 1035–43 CrossRef
- Mannix K, Ahmedzai SH, Anderson H, et al. Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care. Palliat Med 2000; 14: 455–61 CrossRef
- Johnson IS. Use of bisphosphonates for the treatment of metastatic bone pain: a survey of palliative physicians in the UK. Palliat Med 2001; 15: 141–7 CrossRef
- Frediani B, Cavalieri L, Cremonesi G. Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig 2009; 29: 359–79 CrossRef
- McCloskey E, Selby P, de Takats D, et al. Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 2001; 28: 310–5 CrossRef
- McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004; 19: 728–36 CrossRef
- McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in communitydwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007; 22: 135–41 CrossRef
- Frediani B, Falsetti P, Baldi F, et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy x-ray absorptiometry and quantitative ultrasound. Bone 2003; 33: 575–81 CrossRef
- Laitinen K, Patronen A, Harju P, et al. Timing of food intake has a marked effect on the bioavailability of clodronate. Bone 2000; 27: 293–6 CrossRef
- Villikka K, Perttunen K, Rosnell J, et al. The absolute bioavailability of clodronate from two different oral doses. Bone 2002; 31: 418–21 CrossRef
- Giannini S, D’Angelo A, Sartori L, et al. Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss. Obstet Gynecol 1996; 88: 431–6 CrossRef
- Rossini M, Braga V, Gatti D, et al. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone 1999; 24: 125–9 CrossRef
- Herrala J, Puolijoki H, Liippo K, et al. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone 1998; 22: 577–82 CrossRef
- Chesnut 3rd CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144–52 CrossRef
- Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654–61 CrossRef
- Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005; 27: 361–76 CrossRef
- Filipponi P, Cristallini S, Policani G, et al. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass. Bone 2000; 26: 269–74 CrossRef
- Filipponi P, Cristallini S, Rizzello E, et al. Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone 1996; 18: 179–84 CrossRef
- Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993 Sep; 8(9): 1137–48 CrossRef
- Dominguez LJ, Galioto A, Ferlisi A, et al. Intermittent intramuscular clodronate therapy: a valuable option for older osteoporotic women. Age Ageing 2005; 34: 633–6 CrossRef
- Ishijima M, Sakamoto Y, Yamanaka M, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 2009; 85: 398–404 CrossRef
- Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82 CrossRef
- Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008 Apr; 19(4): 385–97 CrossRef
- Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12(7): 519–28 CrossRef
- Effects of Two Administration Schemes of Intramuscular Clodronic Acid on Bone Mineral Density
Clinical Drug Investigation
Volume 31, Issue 1 , pp 43-50
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Osteoporosis and Rheumatologic Instrumental Diagnosis Center, Rheumatology Department, University of Siena, Ospedale ‘Le Scotte’, viale Bracci, 53100, Siena, Italy